Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Long-Term Efficacy of Ramelteon on Endocrine Function in Adult Subjects With Chronic Insomnia

ClinicalTrials.gov ID: NCT00656994

Public ClinicalTrials.gov record NCT00656994. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Safety Study to Evaluate the Long-term Effects of TAK-375 on Endocrine Function in Adult Subjects With Chronic Insomnia

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the long-term effects of Ramelteon, once daily (QD), on endocrine function values.

Study identification

NCT ID
NCT00656994
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Takeda
Industry
Enrollment
122 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 45 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2003 (Type not available)
Primary completion
Jul 2004 (Actual)
Completion
Jul 2004 (Actual)
Last update posted
Feb 28, 2012

2003 – 2004

United States locations

U.S. sites
29
U.S. states
16
U.S. cities
29
Facility City State ZIP Site status
Not listed Birmingham Alabama — —
Not listed Jasper Alabama — —
Not listed Mesa Arizona — —
Not listed Peoria Arizona — —
Not listed La Palma California — —
Not listed Los Angeles California — —
Not listed Riverside California — —
Not listed San Diego California — —
Not listed Denver Colorado — —
Not listed Fort Lauderdale Florida — —
Not listed West Palm Beach Florida — —
Not listed Austell Georgia — —
Not listed Roswell Georgia — —
Not listed Des Moines Iowa — —
Not listed Overland Park Kansas — —
Not listed Prairie Village Kansas — —
Not listed Florence Kentucky — —
Not listed Wentzville Missouri — —
Not listed Kenilworth New Jersey — —
Not listed South Plainfield New Jersey — —
Not listed Cincinnati Ohio — —
Not listed Columbus Ohio — —
Not listed Portland Oregon — —
Not listed Ninety Six South Carolina — —
Not listed Sioux Falls South Dakota — —
Not listed Austin Texas — —
Not listed Fort Worth Texas — —
Not listed San Angelo Texas — —
Not listed Wichita Falls Texas — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00656994, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 28, 2012 · Synced Oct 27, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00656994 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →